BOCA RATON, Fla., Dec. 5, 2016 /PRNewswire/ -- Breckenridge Pharmaceutical, Inc. announced today that it has entered into a multi-product marketing agreement with development and manufacturing partner Gland Pharma Limited for seven (7) injectable products. Under the terms of this agreement, Breckenridge will market and distribute the products under its label in the United States. The deal includes six approved ANDA’s and one tentatively-approved ANDA. The products cover a wide range of indications. This deal further showcases Breckenridge’s entry into the Institutional market and expanding injectable portfolio.
About Breckenridge:
Breckenridge Pharmaceutical, Inc. is a privately-held own label distributor that performs pharmaceutical research and development as well as marketing and distribution in the U.S. The company was founded in 1983 and markets a broad range of generic prescription products in many therapeutic categories. The Breckenridge label is recognized by wholesalers, distributors, chains, and managed care accounts, as well as retail pharmacies nationwide. The company markets over 70 products in a variety of dosage forms including: tablets, capsules, soft gel capsules, liquids, suspensions, ophthalmic, nasal sprays powders, and injectable products. www.bpirx.com
About Gland Pharma Limited:
Established in 1978 and based in Hyderabad, Gland develops and manufactures generic injectables for use in nearly 90 countries on five continents, with a focus on the Indian and US markets. Since 1996, the company has maintained a relationship with the Vetter family in Germany, and by 2003, Gland was the first company in India to get US FDA approval for pharmaceutical liquid injectable products. Gland’s world-class manufacturing facilities have also received approvals from a number of key medical regulatory agencies around the globe including those in Australia, Germany and the UK, in addition to the World Health Organization (“WHO”).
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/breckenridge-pharmaceutical-signs-marketing-agreement-with-gland-pharma-limited-for-seven-injectable-products-300372973.html
SOURCE Breckenridge Pharmaceutical, Inc.
